Company profile · Biotech & medical
Medigen Vaccine Biologics
高端疫苗生物製劑股份有限公司 · 6547
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Medigen Vaccine Biologics develops and mass-produces vaccines and biological products, focusing on infectious diseases such as COVID-19, enteroviruses, dengue fever, and novel influenza.[1]
The company engages in research and development for emerging infectious diseases and collaborates internationally to develop affordable biosimilars.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$100m | +43.2% | -51.7% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | −NT$36m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Medigen Vaccine Biologics Corporation |
|---|---|
| Chinese name | 高端疫苗生物製劑股份有限公司 |
| Stock code | 6547 (TPEx) |
| Industry | Biotech & medical |
| Founded | 12 Oct 2012 |
| Listed | 17 Apr 2018 |
| Paid-in capital | NT$3.3bn |
| Chairman | 張銘政 |
| President | 李思賢 |
| Headquarters | No.68, Shengyi 3rd Rd., Zhubei City, Hsinchu County 30261 , Taiwan |
| Website | http://www.medigenvac.com |
| Official business description | 疫苗研發製造 · 生物製劑研發製造 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 高端疫苗生物製劑股份有限公司 · mops · retrieved 04 Nov 2026
- 高端疫苗生物製劑股份有限公司 · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list